Skip to content
10-Q

Quarterly Report

ARRAY BIOPHARMA INC

0001100412-18-000037

← back to feed
Filed
Oct 30, 2018 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · Oct 26, 2018 213.07M sh
Shares Diluted Q1 2019 · Sep 30, 2018 212.19M sh
Shares Diluted Q1 2019 · Sep 30, 2017 174.77M sh
Capex Q1 2019 · Sep 30, 2018 $265K
Capex Q1 2019 · Sep 30, 2017 $24K
Operating Cash Flow Q1 2019 · Sep 30, 2018 −$34.8M
Operating Cash Flow Q1 2019 · Sep 30, 2017 −$18.04M
Long Term Debt Q1 2019 · Sep 30, 2018 $131.09M
Long Term Debt Q1 2019 · Jun 30, 2018 $93.38M
Long Term Debt restated Q1 2019 · Jun 30, 2017 $93.38M
Short Term Debt Q1 2019 · Sep 30, 2018 $0
Short Term Debt Q1 2019 · Jun 30, 2018 $15.9M
Cash And Equivalents Q1 2019 · Sep 30, 2018 $130.51M
Cash And Equivalents Q1 2019 · Jun 30, 2018 $114.75M
Cash And Equivalents Q1 2019 · Sep 30, 2017 $295.41M
Cash And Equivalents Q1 2019 · Jun 30, 2017 $125.93M
Stockholders Equity Q1 2019 · Sep 30, 2018 $219.07M
Stockholders Equity Q1 2019 · Jun 30, 2018 $219.74M
Current Liabilities Q1 2019 · Sep 30, 2018 $84.77M
Current Liabilities Q1 2019 · Jun 30, 2018 $95.93M
Total Liabilities Q1 2019 · Sep 30, 2018 $265.15M
Total Liabilities Q1 2019 · Jun 30, 2018 $240.62M
Current Assets Q1 2019 · Sep 30, 2018 $476.21M
Current Assets Q1 2019 · Jun 30, 2018 $451.54M
Total Assets Q1 2019 · Sep 30, 2018 $484.22M
Total Assets Q1 2019 · Jun 30, 2018 $460.36M
Eps Diluted Q1 2019 · Sep 30, 2018 −$0.12
Eps Diluted Q1 2019 · Sep 30, 2017 −$0.22
Eps Basic Q1 2019 · Sep 30, 2018 −$0.12
Eps Basic Q1 2019 · Sep 30, 2017 −$0.22
Rd Expense Q1 2019 · Sep 30, 2018 $55.55M
Rd Expense restated Q1 2019 · Sep 30, 2017 $53.2M
Net Income Q1 2019 · Sep 30, 2018 −$24.81M
Net Income Q1 2019 · Sep 30, 2017 −$37.99M
Operating Income Q1 2019 · Sep 30, 2018 −$23.73M
Operating Income Q1 2019 · Sep 30, 2017 −$35.51M